Corcept Therapeutics Incorporated Reports Preliminary Financial Results for the Fourth Quarter and Full Year Ended December 31, 2015; Provides Revenue Guidance for the Fiscal 2016
Corcept reported preliminary revenue of $50.3 million for the full year 2015, an 89% increase from 2014. For the full year, the company reported a preliminary GAAP net loss of $0.06 per share for 2015, compared to a net loss of $0.31 per share in 2014.
The company provided 2016 revenue guidance. 2016 revenue guidance in between $76 million to $81 million.